Medscape is available in 5 Language Editions – Choose your Edition here.


Henoch-Schonlein Purpura

  • Author: Noah S Scheinfeld, JD, MD, FAAD; Chief Editor: Craig B Langman, MD  more...
Updated: Sep 28, 2015

Practice Essentials

Henoch-Schönlein purpura (HSP) is an acute immunoglobulin A (IgA)–mediated disorder characterized by a generalized vasculitis involving the small vessels of the skin, the gastrointestinal (GI) tract, the kidneys, the joints, and, rarely, the lungs and the central nervous system (CNS). See the image below.

Characteristic rash of Henoch-Schönlein purpura. Characteristic rash of Henoch-Schönlein purpura.

Signs and symptoms

The typical prodrome of HSP includes the following:

  • Headache
  • Anorexia
  • Fever

Subsequently, symptoms develop, of which the following are the most common:

  • Rash (95-100% of cases), especially involving the legs; this is the hallmark of the disease
  • Abdominal pain and vomiting (35-85%)
  • Joint pain (60-84%), especially involving the knees and ankles
  • Subcutaneous edema (20-50%)
  • Scrotal edema (2-35%)
  • Bloody stools

Because HSP can affect all organ systems, a full physical examination is indicated. Physical findings in HSP may include the following:

  • Skin findings (usually the first sign of HSP) - Erythematous macular or urticarial lesions, progressing to blanching papules and later to palpable purpura; typically symmetrical and tend distributed in dependent body areas, such as the ankles and lower legs in older children and adults and the back, buttocks, upper extremities, and upper thighs in young children; hives, angioedema, and target lesions can also occur
  • Renal findings - Acute glomerular lesions, including mesangial hypercellularity, endocapillary proliferation, necrosis, cellular crescents, and leukocyte infiltration
  • Gastrointestinal (GI) findings - Abdominal pain, melena, bloody diarrhea, hematemesis, duodenal ulcers, and massive GI hemorrhage
  • Joint findings - Arthralgia and swelling
  • Arthralgia is the presenting feature in as many as 25% of cases. Joints may be swollen, tender, and painful. Warmth, erythema, and effusions are not typically associated with HSP. The knees and ankles are most commonly affected. On rare occasions, symptoms involve the fingers and wrists. Findings are transient but can occur again during active disease. The joints are not permanently deformed.
  • Other findings - Vasculitis involving the myocardium or lungs; stenosing ureteritis, priapism, penile edema, or orchitis; vasculitis involving the central nervous system (CNS) and intracranial hemorrhage; bilateral subperiosteal orbital hematomas; adrenal hematomas; acute pancreatitis as the sole presenting feature (rare); cystic changes of the ovaries

See Presentation for more detail.


No specific diagnostic laboratory test is available to assess for markers of HSP. The following general laboratory tests may be helpful for excluding other diagnoses and evaluating renal function:

  • Antinuclear antibody (ANA) and rheumatoid factor (RF)
  • Factors VIII and XIII
  • Urinalysis
  • Complete blood count (CBC)
  • Platelet count
  • Erythrocyte sedimentation rate (ESR)
  • Stool guaiac test
  • Blood urea nitrogen (BUN) and creatinine
  • Amylase and lipase
  • Electrolytes
  • Plasma D-dimer
  • Plasma thrombin-antithrombin (TAT) complex, prothrombin fragment (PF)-1, and PF-2
  • Prothrombin time (PT) and activated partial thromboplastin time (aPTT)
  • Serum IgA
  • Antistreptolysin O (ASO)
  • CH50
  • C3 and C4
  • Immunocomplexes of IgG and IgA

Imaging modalities that may be considered include the following:

  • Ultrasonography (abdominal, scrotal/testicular)
  • Radiography (chest radiography; plain radiography of the abdomen; contrast radiography of the small intestine; barium enema study)
  • Magnetic resonance imaging (MRI; for assessing neurologic findings)
  • Computed tomography (CT) of the head or abdomen

Other studies that may be warranted are as follows:

  • Endoscopy
  • Renal biopsy (particularly when nephrotic syndrome persists and when renal function deteriorates)

See Workup for more detail.


Treatment remains primarily supportive in most cases, though pharmacotherapy, plasmapheresis, and surgical interventions may also be considered in select cases.

Supportive measures may include the following:

  • Ensuring adequate hydration
  • Monitoring for abdominal and renal complications
  • Treating minor symptoms of arthritis, edema, fever, or malaise
  • Eating a bland diet
  • Discontinuance of any drugs suspected of playing a causative role

Joint and soft tissue discomfort may be reduced by giving analgesics, such as the following:

  • Acetaminophen
  • Ibuprofen
  • Flurbiprofen
  • Ketoprofen
  • Naproxen

Corticosteroids may be considered in the following situations:

  • Persistent nephrotic syndrome
  • Crescents in more than 50% of glomeruli
  • Severe abdominal pain
  • Substantial GI hemorrhage
  • Severe soft tissue edema
  • Severe scrotal edema
  • Neurologic system involvement
  • Intrapulmonary hemorrhage

Other treatment regimens have included IV or oral steroids with or without any of the following:

  • Azathioprine
  • Cyclophosphamide
  • Cyclosporine
  • Dipyridamole
  • High-dose IV immunoglobulin G (IVIg)
  • Danazol
  • Fish oil

Plasmapheresis may be effective in delaying the progression of kidney disease.

Surgical interventions that may be considered in specific circumstances include the following:

  • Surgery for severe bowel ischemia
  • Kidney transplantation for severe renal disease that is resistant to medical therapy
  • Tonsillectomy together with corticosteroid pulse therapy for progressive HSP nephritis

See Treatment and Medication for more detail.



Henoch-Schönlein purpura (HSP; also referred to as Schönlein-Henoch purpura, anaphylactoid purpura, or purpura rheumatica) is an acute immunoglobulin A (IgA)–mediated disorder characterized by a generalized vasculitis involving the small vessels of the skin, the gastrointestinal (GI) tract, the kidneys, the joints, and, rarely, the lungs and the central nervous system (CNS).[1, 2, 3] It is a subset of necrotizing vasculitis characterized by fibrinoid destruction of blood vessels and leukocytoclasis.

The prevalence of HSP peaks in children aged 3-10 years, but the condition is also seen in adults.[4] In the Northern hemisphere, the disease occurs mostly between November and January. The male-to-female ratio is 1.5-2:1.

The dominant clinical features of HSP include cutaneous purpura, arthritis, abdominal pain, GI bleeding, orchitis, and nephritis. In one half to two thirds of children, an upper respiratory tract infection (URTI) precedes the clinical onset of HSP by 1-3 weeks. In general, patients with HSP appear mildly ill. They often have a fever, with a temperature that usually does not exceed 38°C (100.4°F).

HSP is typically an acute, self-limited illness, and treatment is primarily supportive. However, one third of patients have 1 or more recurrences.



IgA clearly plays a critical role in the immunopathogenesis of HSP, as evidenced by increased serum IgA concentrations, IgA-containing circulating immune complexes, and IgA deposition in vessel walls and renal mesangium. HSP is almost exclusively associated with abnormalities involving IgA1, rather than IgA2. The predominance of IgA1 in HSP may be a consequence of abnormal glycosylation of O-linked oligosaccharides unique to the hinge region of IgA1 molecules.

IgA aggregates or IgA complexes with complement deposited in target organs, resulting in elaboration of inflammatory mediators, including vascular prostaglandins such as prostacyclin, may play a central role in the pathogenesis of HSP vasculitis.

A subpopulation of human lymphocytes bears surface Fc and/or C3 receptors (complement receptor lymphocytes), which can bind circulating immune complexes or C3 generated by activation of the alternative complement pathway. Such immune complexes appear in HSP and may be part of the pathogenetic mechanism.

Some have speculated that an antigen stimulates the production of IgA, which, in turn, causes the vasculitis. Allergens, such as foods, horse serum, insect bites, exposure to cold, and drugs (eg, ampicillin, erythromycin, penicillin, quinidine, and quinine), may precipitate the illness.

Infectious causes include bacteria (eg, Haemophilus parainfluenzae, Mycoplasma, Legionella, Yersinia, Shigella, or Salmonella) and viruses (eg, adenoviruses, Epstein-Barr virus [EBV], parvoviruses, or varicella-zoster virus [VZV]). Vaccines such as those against cholera, measles, paratyphoid A and B, typhoid, and yellow fever have also been implicated. Evidence supporting a direct role of herpesvirus, retrovirus, or parvovirus infection in the pathogenesis of HSP is lacking.

Alterations in the production of interleukins (ILs) and growth factors may also play a pathogenetic role. Tumor necrosis factor (TNF), IL-1, and IL-6 may mediate the inflammatory process present in HSP. Transforming growth factor (TGF)–β is a recognized stimulant of IgA production. The elevated levels of hepatocyte growth factor present during the acute phase of HSP may reflect endothelial-cell damage or dysfunction. Increased levels of vascular endothelial growth factor (VEGF) may at least partly induce these changes.

Cytokines have been implicated in the pathogenesis of HSP, and endothelins (ETs), which are vasoconstrictor hormones produced by endothelial cells, may also have a role. levels of ET-1 are substantially higher during the acute phase of the disease than during remission or in a control group of children. However, ET-1 levels do not appear to be correlated with morbidity, severity of disease, or acute-phase reactant response.

Although several lines of evidence suggest a genetic susceptibility to HSP, the fundamental basis for this abnormality remains unclear.

A functional correlation of the IL1RN-2 allele and IL-1ra production in patients with IgA nephropathy and HSP nephritis (HSPN) has been described. Therefore, gene polymorphism may contribute to the diversity of clinical responses to inflammatory stimulation.

The prevalence of the human parvovirus B19 component NS1 gene in patients with HSP and hypersensitivity vasculitis is increased.

Results support a role of human leukocyte antigen (HLA)-B35 in the susceptibility to nephritis in unselected patients with HSP.

Researchers are currently investigating the importance of nitric oxide (NO) production in disease activity. Inducible NO synthase polymorphism has been associated with susceptibility to HSP in northwestern Spain. Aliyazicioglu et al have suggested that leptin and NO may play a role in the immunoinflammatory process of HSP, especially in the acute phase.[5]

HSP that is likely due to montelukast has been noted in patients who present with subacute intestinal obstruction.

Yilmaz et al examined 28 children with HSP and 79 healthy children to evaluate activities of protein C, free-protein S, and antithrombin; resistance to activated protein C; and levels of fibrinogen.[6] D-dimer, thrombin-antithrombin (TAT) complex, prothrombin fragment (PF)-1, PF-2, and von Willebrand factor antigen (vWAg) and its activity (RiCof) were also investigated.

The investigators found that in patients with HSP, fibrinogen, D-dimer, TAT complex, PF-1, PF-2, vWAg, and RiCof levels were significantly higher during the acute phase than during the recovery phase and were significantly higher than those of control subjects.[6] The severity of disease was significantly correlated with TAT, PF-1, PF-2, vWAg, and D-dimer levels.

Higher levels of matrix metalloproteinase (MMP)-9 levels in urine and serum appear to increase nephrologic severity in children with HSP.

Use of TNF-α blockers such as adalimumab may increase the risk of developing HSP.

HSP versus IgA nephropathy

HSP and IgA nephropathy appear to be related disorders. However, the precise relation between them requires further definition. The question has been raised as to whether HSP and IgA nephropathy are 2 aspects of a single disease entity or 2 distinct entities. The following commonalities and differences have been noted:

  • IgA nephropathy almost exclusively involves young adults and typically affects only the kidneys, whereas HSP affects mostly children and involves the skin and connective tissues, GI tract, joints, and scrotum, as well as the kidneys [3, 7, 8]
  • The occurrence of extrarenal manifestations in IgA nephropathy is similar to that in HSP
  • IgA nephropathy has developed in patients with a history of HSP, and HSP and IgA nephropathy have occurred in the same families; in a survey of 40 families in which 2 or more members had IgA nephropathy, 5 presented with HSP [9]
  • Patients with HSP who undergo renal transplantation develop IgA deposits in the graft
  • The prevalence of both conditions is high in certain geographic areas
  • Similar changes in the IgA system (ie, high IgA, IgA-1C, IgA1-IC, IgA-fibronectin aggregates, aberrantly glycosylated IgA in the circulation) occur in the 2 diseases [10, 11, 12]
  • Cystic changes in the ovaries of a prepubertal girl with HSP have been recorded

Overall, the data tend to support the view that HSP and IgA nephropathy are distinct diseases.[13] Zhou et al examined 31 children aged 3-15 years with IgA nephropathy and 120 children aged 4-15 years with HSP, noting their clinical manifestations, blood biochemistries, serum immunology, and follow-up data.[14] Renal pathologic findings on light microscopy, immunofluorescence study, and electron microscopy were analyzed and compared between 31 children with IgA nephropathy and 32 children with HSP.

The age of onset was greater than 12 years in 25.8% of the children with IgA nephropathy but in only 10% of those with HSP.[14] Clinical patterns of IgA nephropathy were similar to those of HSP, but extrarenal manifestations were observed more often in patients with HSP.

All of the HSP patients had skin purpura, 59% had GI symptoms, and 47% had arthralgia. Abdominal pain occurred in only 3.2% of children with IgA nephropathy.[14] In patients with IgA nephrology and in patients with HSP, renal pathology revealed global sclerosis in 35.5% and 3.1%, mesangial sclerosis in 41.9% and 6.3%, endothelial proliferation in 29% and 65.6%, and thin basement-membrane nephropathy in 6.5% and 0%, respectively.

In HSP, electronically dense deposits in HSP were sparse, loose, and widely spread in the glomerular mesangium, in the subendothelial area, and even in the intrabasement membranes, whereas in IgA nephropathy, the deposits were dense, lumpy, and mostly limited to mesangium and paramesangium.[14]

Immunoglobulin G (IgG) was found in glomerular immune deposits in 71.9% of patients with HSP but in only 19.4% of patients with IgA nephropathy.[14] No IgG deposit was observed in 81.6% of those with IgA nephropathy; most had IgA and immunoglobulin M (IgM) or C3 deposits. Predominant IgG deposits were found in 12.5% of HSP patients, with relatively weak IgA deposits. Moreover, 6.3% of HSP patients had linear IgG deposits in the glomerular capillary wall, a finding that was not noted in patients with IgA nephropathy.

The rate of complete remission was 72.5% in patients with HSP at an average of 20 months’ follow-up; the corresponding rate was 19.4% in those with IgA nephropathy after 34 months’ follow-up.[14] Moreover, 64.5% of patients with IgA nephropathy had consistent hematuria and proteinuria, and 16.1% had active nephritides.

The important clinicopathologic differences Zhou et al found between HSP and IgA nephropathy argue against the single-disease hypothesis.



The etiology of HSP remains to be clearly defined but is thought to be multifactorial, with genetic, environmental, and antigenic components. More than 75% of patients report antecedent URTI, pharyngeal infection, or GI infection. Multiple bacterial and viral infectious agents have been associated with the development of HSP, and cases also have been reported after drug ingestions and vaccinations.[15]

Infections that may precede the development of HSP include the following:

Vaccinations that may precede the development of HSP include the following:

Environmental exposure to the following may precede the development of HSP:

  • Drugs (eg, ampicillin, erythromycin, penicillin, quinidine, quinine, losartan, and cytarabine [20] )
  • Foods
  • Horse serum
  • Cold exposure
  • Insect bites

Glomerulocystic kidney disease has also been noted.



United States statistics

In the United States, the prevalence of HSP is approximately 14-15 cases per 100,000 population.

International statistics

In the United Kingdom, the estimated annual incidence of HSP is 20.4 cases per 100,000 population.[21] In a Norwegian community hospital, the prevalence of Henoch-Schoenlein purpura was 3.3 cases per 100,000 inhabitants.[22]

In a study that examined the renal biopsy results of 65 children younger than 18 years obtained by the Clinical Hospital in the Croatian region of Dalmatia over a 10-year period (1995-2005), 10.8% of glomerulonephritis cases were due to HSP.[23]

Nong et al reviewed the records of 107 Taiwanese pediatric patients diagnosed with HSP between 1991 and 2005 who had a mean age of 6.2 ± 2.5 years (range, 2-13 years); the male-to-female ratio was 1:0.7.[24] The primary symptoms included the following:

  • Rashes (95.3%)
  • GI symptoms (72.0%)
  • Joint involvement (46.7%)
  • Kidney involvement (28.0%)

The most common first manifestations were as follows:

  • Rashes (56.1%)
  • GI symptoms (35.5%)
  • Joint involvement (12.1%)

From January 1983 to June 2004, Suehiro et al followed 4502 patients at the Pediatric Rheumatology clinic in Brazil.[25] A diagnosis of HSP was made in 203 cases (4.5%); 5 patients (0.1%) had acute hemorrhagic edema of infancy (AHEI). All patients with AHEI were male, and the mean age at onset was 18 months (range, 8-21 months).

Age-related demographics

HSP primarily affects children; it may be seen in adults, but much less frequently.[2, 8] In the United States, the prevalence peaks in children aged 5 years. Approximately 75% of cases occur in children aged 2-11 years; HSP is rare in infants and young children. Older age at the onset of HSP is associated with the development of chronic renal disease.[26] AHEI, a related but milder condition, occurs in infants younger than 2 years.[27]

Ghrahani et al conducted a retrospective study in children with HSP in Hasan Sadikin Hospital from 2006 to 2011 to evaluate renal involvement in children with HSP. The authors reported that there were 128 patients with an age range from 6 month to 15 years. Peak morbidity was between 5-10 years old. In most patients (71%) purpura was the first symptom. Seventy-one patients (44.5%) had arthritis and 89 patients (69.5%) had abdominal pain, while renal involvement was in 28 patients (21.8%). Gastrointestinal manifestations tend to manifest in patients less than 5 years old, while renal involvement tend to manifest in age group 11-15 years old. The authors concluded that renal involvement in children with HSP is more common in age group 11 to 15 years old.[28]

Sex-related demographics

HSP occurs more often in boys than in girls. In children, the male-to-female ratio is 1.5-2:1. In adults, the male-to-female ratio is approximately 1:1.

Race-related demographics

Whites are affected more often than blacks.

In a study from Thailand, patients most commonly presented between the ages of 3 and 5 years.[29] Frequency peaked from December to February. Organs involved included the skin (100%), GI tract (74.5%), and kidneys (46.8%). Joints were also affected (42.6%). Renal involvement was detected within the first 2 months in 16 patients (72.7%); however, it was delayed until 6 months after diagnosis in 6 patients.

No risk factors for renal involvement could be identified in this study.[29] Mean follow-up time was 2.6 years (range, 1-5 years). Residual renal disease occurred in 6 (38%) of 16 patients, but none had end-stage renal disease (ESRD).

In a study from China, a male predominance was observed in children but not in adults.[30] Preceding infection was noted in 40.5% of children and 31.6% of adults; 8.3% of children and 13.2% of adults were receiving medication at the onset of the disease.

The investigators found that abdominal pain was more common in children than adults (70.2% vs 28.9%), but renal involvement was more common and severe in adults than in children; this involvement manifested as frequent hypertension and heavy proteinuria.[30] During acute attacks, leukocytosis, thrombocytosis, and elevated serum C-reactive protein (CRP) levels were most frequently observed in children, whereas elevated serum IgA and cryoglobulin levels were most common in adults.

A study of 450 cases from Turkey showed that girls, patients with atypical presentations, and patients undergoing early corticosteroid treatment had an increased risk of developing kidney disease; relapses occurred more often in children treated with corticosteroids.[31]

Familial kindreds with HSP have been noted in Taiwanese aboriginal people.[32]



HSP is generally a benign disease with an excellent prognosis. Spontaneous resolution is usual: Most patients experience complete resolution of symptoms within 8 weeks, and probably fewer than 5% experience chronic symptoms. Initial attacks of HSP can last several months, and relapses are possible. HSP is fatal only in the rarest of cases.

A clinical course with complete resolution of the disease usually occurs in patients with the following:

  • Mild kidney involvement
  • No neurologic complications
  • Disease that lasts less than 4-6 weeks initially

Children younger than 3 years usually have a shorter, milder course than older patients do, as well as fewer recurrences.

Recurrences occur in as many as 50% of patients within 6 weeks but can happen as late as 7 years after the initial disease. The higher the number of recurrences, the higher the likelihood of permanent renal damage.

Although HSP generally resolves without permanent consequences, serious GI and renal complications may occur. Potential GI complications include intussusception (usually ileoileal), bowel infarction, bowel perforation, hydrops of the gallbladder, pancreatitis, and massive GI bleeding.

Kidney damage related to HSP is the primary cause of morbidity and mortality. As many as 15% of patients may have long-term renal insufficiency, but no more than 1-2% will have ESRD. As many as 20% of children who have HSP and are treated in specialized centers require hemodialysis. The renal prognosis appears to be worse in adults than in children (in particular, those aged ≤6 years).

Predictors of serious nephropathy or ESRD include the following:

  • Bloody stools
  • Rash persistence
  • Hematuria and proteinuria (patients with only hematuria do not develop ESRD, but about 15% of patients with hematuria and proteinuria do develop ESRD)
  • Signs of nephritis or nephrotic syndrome (50% of patients progress to ESRD within 10 years)
  • Renal biopsy with extensive glomerular crescents

Patients with a normal urinalysis at 6 months and without previous renal involvement have not gone on to develop kidney problems.[33]

Pregnant women who had HSP during childhood appear to be at increased risk for developing hypertension and proteinuria during pregnancy.[34]


Patient Education

Patients should be informed that the disease is most likely to resolve with few residual adverse effects but that relapses are possible. The clinician should explain that severe kidney involvement is rare but that if it does occur, aggressive treatment may be required.

For patient education resources, see Blood in the Urine.

Contributor Information and Disclosures

Noah S Scheinfeld, JD, MD, FAAD Assistant Clinical Professor, Department of Dermatology, Weil Cornell Medical College; Consulting Staff, Department of Dermatology, St Luke's Roosevelt Hospital Center, Beth Israel Medical Center, New York Eye and Ear Infirmary; Assistant Attending Dermatologist, New York Presbyterian Hospital; Assistant Attending Dermatologist, Lenox Hill Hospital, North Shore-LIJ Health System; Private Practice

Noah S Scheinfeld, JD, MD, FAAD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: Abbvie<br/>Received income in an amount equal to or greater than $250 from: Optigenex<br/>Received salary from Optigenex for employment.


Elena L Jones, MD Clinical Assistant Professor of Dermatology, Columbia University College of Physicians and Surgeons; Clinic Chief, Department of Dermatology, St Luke's-Roosevelt Hospital Center

Disclosure: Nothing to disclose.

Chief Editor

Craig B Langman, MD The Isaac A Abt, MD, Professor of Kidney Diseases, Northwestern University, The Feinberg School of Medicine; Division Head of Kidney Diseases, The Ann and Robert H Lurie Children's Hospital of Chicago

Craig B Langman, MD is a member of the following medical societies: American Academy of Pediatrics, American Society of Nephrology, International Society of Nephrology

Disclosure: Received income in an amount equal to or greater than $250 from: Alexion Pharmaceuticals; Raptor Pharmaceuticals; Eli Lilly and Company; Dicerna<br/>Received grant/research funds from NIH for none; Received grant/research funds from Raptor Pharmaceuticals, Inc for none; Received grant/research funds from Alexion Pharmaceuticals, Inc. for none; Received consulting fee from DiCerna Pharmaceutical Inc. for none.


Jeffrey L Arnold, MD, FACEP Chairman, Department of Emergency Medicine, Santa Clara Valley Medical Center

Jeffrey L Arnold, MD, FACEP is a member of the following medical societies: American Academy of Emergency Medicine and American College of Physicians

Disclosure: Nothing to disclose.

Philip Bossart, MD Professor, Department of Surgery, Division of Emergency Medicine, University of Utah Hospital, University of Utah School of Medicine

Philip Bossart, MD is a member of the following medical societies: American College of Emergency Physicians

Disclosure: Nothing to disclose.

Steven C Dronen, MD, FAAEM Chair, Department of Emergency Medicine, LeConte Medical Center

Steven C Dronen, MD, FAAEM is a member of the following medical societies: American Academy of Emergency Medicine and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Pamela L Dyne, MD Professor of Clinical Medicine/Emergency Medicine, University of California, Los Angeles, David Geffen School of Medicine; Attending Physician, Department of Emergency Medicine, Olive View-UCLA Medical Center

Pamela L Dyne, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Gina M Forte Medical Assistant, The Skin Cancer Surgery Center

Disclosure: Nothing to disclose.

Edmond A Hooker II, MD, DrPH, FAAEM Associate Professor, Department of Health Services Administration, Xavier University, Cincinnati, Ohio; Assistant Professor, Department of Emergency Medicine, University of Cincinnati College of Medicine

Edmond A Hooker II, MD, DrPH, FAAEM is a member of the following medical societies: American Academy of Emergency Medicine, American Public Health Association, Society for Academic Emergency Medicine, and Southern Medical Association

Disclosure: Nothing to disclose.

William D James, MD Paul R Gross Professor of Dermatology, Vice-Chairman, Residency Program Director, Department of Dermatology, University of Pennsylvania School of Medicine

William D James, MD is a member of the following medical societies: American Academy of Dermatology and Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Heather Kesler DeVore, MD Assistant Professor, Clinical Attending Physician, Department of Emergency Medicine, Georgetown University Hospital and Washington Hospital Center

Heather Kesler DeVore, MD is a member of the following medical societies: Emergency Medicine Residents Association and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Andrew D Montemarano, DO Consulting Staff, The Skin Cancer Surgery Center

Andrew D Montemarano, DO is a member of the following medical societies: American Academy of Dermatology, American College of Mohs Micrographic Surgery and Cutaneous Oncology, American Society for Dermatologic Surgery, and MedChi

Disclosure: Nothing to disclose.

Richard Neiberger, MD, PhD Director of Pediatric Renal Stone Disease Clinic, Associate Professor, Department of Pediatrics, Division of Nephrology, University of Florida College of Medicine and Shands Hospital

Richard Neiberger, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American Federation for Medical Research, American Medical Association, American Society of Nephrology, American Society of Pediatric Nephrology, Christian Medical & Dental Society, Florida Medical Association, International Society for Peritoneal Dialysis, International Society of Nephrology, National Kidney Foundation, New York Academy of Sciences, Shock Society, Sigma Xi, Southern Medical Association, Southern Society for Pediatric Research, and Southwest Pediatric Nephrology Study Group

Disclosure: Nothing to disclose.

Julia R Nunley, MD Professor, Program Director, Dermatology Residency, Department of Dermatology, Virginia Commonwealth University Medical Center

Julia R Nunley, MD is a member of the following medical societies: American Academy of Dermatology, American College of Physicians, American Society of Nephrology, International Society of Nephrology, Medical Dermatology Society, Medical Society of Virginia, National Kidney Foundation, Phi Beta Kappa, and Women's Dermatologic Society

Disclosure: Nothing to disclose.

Stacy Sawtelle, MD Clinical Instructor, Department of Emergency Medicine, University of California, San Francisco, School of Medicine

Disclosure: Nothing to disclose.

Debra Slapper, MD Consulting Staff, Department of Emergency Medicine, St Anthony's Hospital

Debra Slapper, MD is a member of the following medical societies: American Academy of Emergency Medicine

Disclosure: Nothing to disclose.

Adrian Spitzer, MD Clinical Professor Emeritus, Department of Pediatrics, Albert Einstein College of Medicine

Adrian Spitzer, MD is a member of the following medical societies: American Academy of Pediatrics, American Federation for Medical Research, American Pediatric Society, American Society of Nephrology, American Society of Pediatric Nephrology, International Society of Nephrology, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Michael J Wells, MD Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine

Michael J Wells, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, and Texas Medical Association

Disclosure: Nothing to disclose.

Robert J Willard, MD Dermatologist and Mohs Surgeon, Private Practice, Dermatology and Mohs Surgery Center, PC

Robert J Willard, MD is a member of the following medical societies: American Academy of Dermatology, American College of Mohs Micrographic Surgery and Cutaneous Oncology, and American Society for Dermatologic Surgery

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Wayne Wolfram, MD, MPH Professor, Department of Emergency Medicine, Mercy St Vincent Medical Center; Chairman, Pediatric Institutional Review Board, Mercy St Vincent Medical Center, Toledo, Ohio

Wayne Wolfram, MD, MPH, is a member of the following medical societies: American Academy of Emergency Medicine, American Academy of Pediatrics, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

David Timothy Woodley, MD Professor and Chair, Department of Dermatology, Keck School of Medicine of the University of Southern California

David Timothy Woodley, MD is a member of the following medical societies: American Academy of Dermatology, American Association for the Advancement of Science, American College of Emergency Physicians, American College of Physicians, American Federation for Medical Research, American Society for Clinical Investigation, New York Academy of Medicine, Society for Investigative Dermatology, and Southern Medical Association

Disclosure: Lotus Tissue Repair Ownership interest owner and advisor

  1. Henoch EH. Uber ein eigenthe Form von Purpura. Berl Klin Wochenschr. 1974. 11:641-3.

  2. Blanco R, Martínez-Taboada VM, Rodríguez-Valverde V, García-Fuentes M, González-Gay MA. Henoch-Schönlein purpura in adulthood and childhood: two different expressions of the same syndrome. Arthritis Rheum. 1997 May. 40(5):859-64. [Medline].

  3. Szer IS. Henoch-Schönlein purpura. Curr Opin Rheumatol. 1994 Jan. 6(1):25-31. [Medline].

  4. Trapani S, Micheli A, Grisolia F, Resti M, Chiappini E, Falcini F, et al. Henoch Schonlein purpura in childhood: epidemiological and clinical analysis of 150 cases over a 5-year period and review of literature. Semin Arthritis Rheum. 2005 Dec. 35(3):143-53. [Medline].

  5. Aliyazicioglu Y, Ozkaya O, Yakut H, et al. Leptin levels in Henoch-Schonlein purpura. Clin Rheumatol. 2007 Mar. 26(3):371-5. [Medline].

  6. Yilmaz D, Kavakli K, Ozkayin N. The elevated markers of hypercoagulability in children with Henoch-Schonleinpurpura. Pediatr Hematol Oncol. 2005 Jan-Feb. 22(1):41-8. [Medline].

  7. Gedalia A. Henoch-Schönlein purpura. Curr Rheumatol Rep. 2004 Jun. 6(3):195-202. [Medline].

  8. Pillebout E, Thervet E, Hill G, Alberti C, Vanhille P, Nochy D. Henoch-Schönlein Purpura in adults: outcome and prognostic factors. J Am Soc Nephrol. 2002 May. 13(5):1271-8. [Medline].

  9. Levy M. Familial cases of Berger's disease and anaphylactoid purpura. Kidney Int. 2001 Oct. 60(4):1611-2. [Medline].

  10. Coppo R, Basolo B, Piccoli G, et al. IgA1 and IgA2 immune complexes in primary IgA nephropathy and Henoch-Schonlein nephritis. Clin Exp Immunol. 1984 Sep. 57(3):583-90. [Medline].

  11. Davin JC, Malaise M, Foidart J, Mahieu P. Anti-alpha-galactosyl antibodies and immune complexes in children with Henoch-Schonlein purpura or IgA nephropathy. Kidney Int. 1987 May. 31(5):1132-9. [Medline].

  12. Jennette JC, Wieslander J, Tuttle R, Falk RJ. Serum IgA-fibronectin aggregates in patients with IgA nephropathy and Henoch-Schonlein purpura: diagnostic value and pathogenic implications. The Glomerular Disease Collaborative Network. Am J Kidney Dis. 1991 Oct. 18(4):466-71. [Medline].

  13. Calvo-Río V, Loricera J, Martín L, Ortiz-Sanjuán F, Alvarez L, González-Vela MC, et al. Henoch-Schönlein purpura nephritis and IgA nephropathy: a comparative clinical study. Clin Exp Rheumatol. 2013 Jan-Feb. 31(1 Suppl 75):S45-51. [Medline].

  14. Zhou JH, Huang AX, Liu TL. [A clinico-pathological study comparing Henoch-Schonlein purpura nephritis with IgA nephropathy in children]. Zhonghua Er Ke Za Zhi. 2003 Nov. 41(11):808-12. [Medline].

  15. Rigante D, Castellazzi L, Bosco A, Esposito S. Is there a crossroad between infections, genetics, and Henoch-Schönlein purpura?. Autoimmun Rev. 2013 Aug. 12(10):1016-21. [Medline].

  16. Hernando-Harder AC, Booken N, Goerdt S, Singer MV, Harder H. Helicobacter pylori infection and dermatologic diseases. Eur J Dermatol. 2009 Jun. [Medline].

  17. Hoshino C. Adult onset Schonlein-Henoch purpura associated with Helicobacter pylori infection. Intern Med. 2009 May. 10:847-51. [Medline].

  18. Mytinger JR, Patterson JW, Thibault ES, Webb J, Saulsbury FT. Henoch-Schönlein purpura associated with Helicobacter pylori infection in a child. Pediatr Dermatol. 2008 Nov-Dec. 6:630-2. [Medline].

  19. Xiong LJ, Tong Y, Wang ZL, Mao M. Is Helicobacter pylori infection associated with Henoch-Schonlein purpura in Chinese children? a meta-analysis. World J Pediatr. 2012 Nov. 8:301-8. [Medline].

  20. Aktas B, Topcuoglu P, Kurt OK, Ensari A, Demirer T. Severe henoch-schonlein purpura induced by cytarabine. Ann Pharmacother. 2009 Apr. 4:792-3. [Medline].

  21. Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch-Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet. 2002 Oct 19. 360(9341):1197-202. [Medline].

  22. Haugeberg G, Bie R, Bendvold A, et al. Primary vasculitis in a Norwegian community hospital: a retrospective study. Clin Rheumatol. 1998. 17(5):364-8. [Medline].

  23. Bazina M, Glavina-Durdov M, Scukanec-Spoljar M, et al. Epidemiology of renal disease in children in the region of Southern Croatia: A 10-year review of regional renal biopsy databases. Med Sci Monit. 2007 Mar 27. 13(4):CR172-176. [Medline].

  24. Nong BR, Huang YF, Chuang CM, Liu CC, Hsieh KS. Fifteen-year experience of children with Henoch-Schonlein purpura in southern Taiwan, 1991-2005. J Microbiol Immunol Infect. 2007 Aug. 40(4):371-6. [Medline].

  25. Suehiro RM, Soares BS, Eisencraft AP, Campos LM, Silva CA. Acute hemorrhagic edema of childhood. Turk J Pediatr. 2007 Apr-Jun. 49(2):189-92. [Medline].

  26. Chen O, Zhu XB, Ren P, Wang YB, Sun RP, Wei DE. Henoch Schonlein Purpura in children: clinical analysis of 120 cases. Afr Health Sci. 2013 Mar. 13(1):94-9. [Medline]. [Full Text].

  27. Al Sufyani MA. Acute hemorrhagic edema of infancy: unusual scarring and review of the English language literature. Int J Dermatol. 2009 Jun. 6:617-22. [Medline].

  28. Ghrahani R, Ledika MA, Sapartini G, Setiabudiawan B. Age of onset as a risk factor of renal involvement in Henoch-Schönlein purpura. Asia Pac Allergy. 2014 Jan. 4(1):42-7. [Medline]. [Full Text].

  29. Pabunruang W, Treepongkaruna S, Tangnararatchakit K, et al. Henoch-Schonlein purpura: clinical manifestations and long-term outcomes in Thai children. J Med Assoc Thai. 2002 Nov. 85 Suppl 4:S1213-8. [Medline].

  30. Lin SJ, Huang JL. Henoch-Schonlein purpura in Chinese children and adults. Asian Pac J Allergy Immunol. 1998 Mar. 16(1):21-5. [Medline].

  31. Anil M, Aksu N, Kara OD, et al. Henoch-Schonlein purpura in children from western Turkey: a retrospective analysis of 430 cases. Turk J Pediat. 51. 2009:429-36. [Medline].

  32. Chen YH, Lin TY, Chen CJ, Chen LK, Jan RH. Familial cases of Henoch-Schönlein purpura in Taiwanese Aborigines. Pediatr Neonatol. 2012 Oct. 53:320-4. [Medline].

  33. Narchi H. Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child. 2005 Sep. 90(9):916-20. [Medline]. [Full Text].

  34. McCarthy HJ, Tizard EJ. Clinical practice: Diagnosis and management of Henoch-Schönlein purpura. Eur J Pediatr. 2010 Jun. 169(6):643-50. [Medline].

  35. Thrash B, Patel M, Shah KR, Boland CR, Menter A. Cutaneous manifestations of gastrointestinal disease: part II. J Am Acad Dermatol. 2013 Feb. 68(2):211.e1-33; quiz 244-6. [Medline].

  36. Chan KH, Tang WY, Lo KK. Bullous lesions in Henoch-Schonlein purpura. Pediatr Dermatol. 2007 May-Jun. 24(3):325-6. [Medline].

  37. Kim CJ, Chung HY, Kim SY, et al. Acute appendicitis in Henoch-Schonlein purpura: a case report. J Korean Med Sci. 2005 Oct. 20(5):899-900. [Medline].

  38. Bilici S, Akgun C, Melek M, et al. Acute appendicitis in two children with Henoch-Schönlein purpura. Paediatr Int Child Health. 2012. 32(4):244-5. [Medline].

  39. Ha TS, Lee JS. Scrotal involvement in childhood Henoch-Schonlein purpura. Acta Paediatr. 2007 Apr. 96(4):552-5. [Medline].

  40. Ozkaya O, Bek K, Alaca N, et al. Cerebral vasculitis in a child with Henoch-Schonlein purpura and familial Mediterranean fever. Clin Rheumatol. 2007 Oct. 26(10):1729-32. [Medline].

  41. Takeuchi S, Soma Y, Kawakami T. IgM in lesional skin of adults with Henoch-Schönlein purpura is an indication of renal involvement. J Am Acad Dermatol. 2010 Dec. 63(6):1026-9. [Medline].

  42. ALLEN DM, DIAMOND LK, HOWELL DA. Anaphylactoid purpura in children (Schonlein-Henoch syndrome): review with a follow-up of the renal complications. AMA J Dis Child. 1960 Jun. 99:833-54. [Medline].

  43. Prais D, Amir J, Nussinovitch M. Recurrent Henoch-Schonlein purpura in children. J Clin Rheumatol. 2007 Feb. 13(1):25-8. [Medline].

  44. Szeto CC, Choi PC, To KF, et al. Grading of acute and chronic renal lesions in Henoch-Schönlein purpura. Mod Pathol. 2001 Jul. 14(7):635-40. [Medline].

  45. Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, Holtta T, et al. Renal manifestations of Henoch-Schonlein purpura in a 6-month prospective study of 223 children. Arch Dis Child. 2010 Nov. 95(11):877-82. [Medline].

  46. Makay B, Turkyilmaz Z, Duman M, Unsal E. Mean platelet volume in Henoch-Schonlein purpura: relationship to gastrointestinal bleeding. Clin Rheumatol. 2009 Oct. 28(10):1225-8. [Medline].

  47. Soyer T, Egritas O, Atmaca E, Akman H, Ozturk H, Tezic T. Acute pancreatitis: a rare presenting feature of Henoch Schonlein purpura. J Paediatr Child Health. 2008 Mar. 3:152-3. [Medline].

  48. Nader NS, Matsumoto JM, Lteif A. Cystic changes in the ovaries of a pre-pubertal girl with Henoch-Schonlein purpura. J Pediatr Endocrinol Metab. 2010 May. 23(5):517-9. [Medline].

  49. Tudorache E, Azema C, Hogan J, Wannous H, Aoun B, Decramer S, et al. Even mild cases of paediatric Henoch-Schönlein purpura nephritis show significant long-term proteinuria. Acta Paediatr. 2015 Aug. 104 (8):843-8. [Medline].

  50. Coppo R, Andrulli S, Amore A, et al. Predictors of outcome in Henoch-Schonlein nephritis in children and adults. Am J Kidney Dis. 2006 Jun. 47(6):993-1003. [Medline].

  51. Matayoshi T, Omi T, Sakai N, Kawana S. Clinical significance of blood coagulation factor XIII activity in adult Henoch-Schönlein purpura. J Nippon Med Sch. 2013. 80(4):268-78. [Medline].

  52. Prenzel F, Pfaffle R, Thiele F, Schuster V. Decreased factor XIII activity during severe Henoch-Schoenlein purpura -- does it play a role?. Klin Padiatr. 2006 May-Jun. 218(3):174-6. [Medline].

  53. Shin JI, Lee JS. Could measurement of factor XIII level detect the vasculitic process of Henoch-Schonlein purpura without skin rash. Acta Paediatr. 2008 Apr. 4:395. [Medline].

  54. Nchimi A, Khamis J, Paquot I, Bury F, Magotteaux P. Significance of bowel wall abnormalities at ultrasound in Henoch-Schonlein purpura. J Pediatr Gastroenterol Nutr. 2008 Jan. 46(1):48-53. [Medline].

  55. O'Brien WM, O'Connor KP, Horan JJ, Eggli DF, Gibbons MD. Acute scrotal swelling in Henoch-Schonlein syndrome: evaluation with testicular scanning. Urology. 1993 Apr. 41(4):366-8. [Medline].

  56. Chartapisak W, Opastiraku S, Willis NS, Craig JC, Hodson EM. Prevention and treatment of renal disease in Henoch-Schönlein purpura: a systematic review. Arch Dis Child. 2009 Feb. 94(2):132-7. [Medline].

  57. Saulsbury FT. Clinical update: Henoch-Schönlein purpura. Lancet. 2007 Mar 24. 369(9566):976-8. [Medline].

  58. Huber AM, King J, McLaine P, Klassen T, Pothos M. A randomized, placebo-controlled trial of prednisone in early Henoch Schönlein Purpura [ISRCTN85109383]. BMC Med. 2004 Apr 2. 2:7. [Medline]. [Full Text].

  59. Bogdanovic R. Henoch-Schönlein purpura nephritis in children: risk factors, prevention and treatment. Acta Paediatr. 2009 Dec. 98(12):1882-9. [Medline].

  60. Chartapisak W, Opastirakul S, Hodson EM, Willis NS, Craig JC. Interventions for preventing and treating kidney disease in Henoch-Schonlein Purpura (HSP). Cochrane Database Syst Rev. 2009. Chartapisak W, Opastirakul S, Hodson EM, Willis NS, Craig JC:CD005128. [Medline].

  61. Ronkainen J, Koskimies O, Ala-Houhala M, Antikainen M, Merenmies J, Rajantie J, et al. Early prednisone therapy in Henoch-Schönlein purpura: a randomized, double-blind, placebo-controlled trial. J Pediatr. 2006 Aug. 149(2):241-7. [Medline].

  62. Bowman P, Quinn M. Question 1: Should steroids be used to treat abdominal pain caused by Henoch-Schonlein purpura?. Arch Dis Child. 2012 Nov. 97(11):999-1000. [Medline].

  63. Faedda R, Pirisi M, Satta A, et al. Regression of Henoch-Schonlein disease with intensive immunosuppressive treatment. Clin Pharmacol Ther. 1996 Nov. 60(5):576-81. [Medline].

  64. Ohtsuka T. Successful oral cyclosporin therapy for Henoch-Schonlein purpura nephropathy. J Dermatol. 2009 May. 36(5):314-6. [Medline].

  65. [Guideline] Anstey AV, Wakelin S, Reynolds NJ. Guidelines for prescribing azathioprine in dermatology. Br J Dermatol. 2004 Dec. 151(6):1123-32. [Medline]. [Full Text].

  66. Zaffanello M, Brugnara M, Franchini M. Therapy for children with henoch-schonlein purpura nephritis: a systematic review. ScientificWorldJournal. 2007. 7:20-30. [Medline].

  67. Jauhola O, Ronkainen J, Autio-Harmainen H, Koskimies O, Ala-Houhala M, Arikoski P, et al. Cyclosporine A vs. methylprednisolone for Henoch-Schönlein nephritis: a randomized trial. Pediatr Nephrol. Dec 2011. 26:2159-66. Erratum in: Pediatr Nephrol. 2011 Dec;26(12):2263-4. [Medline].

  68. Flynn JT, Smoyer WE, Bunchman TE, Kershaw DB, Sedman AB. Treatment of Henoch-Schönlein Purpura glomerulonephritis in children with high-dose corticosteroids plus oral cyclophosphamide. Am J Nephrol. 2001 Mar-Apr. 21(2):128-33. [Medline].

  69. Fagbemi AA, Torrente F, Hilson AJ, Thomson MA, Heuschkel RB, Murch SH. Massive gastrointestinal haemorrhage in isolated intestinal Henoch-Schonlein purpura with response to intravenous immunoglobulin infusion. Eur J Pediatr. 2007 Sep. 166(9):915-9. [Medline].

  70. De Maddi F, Dinardo R, Buonocore MC, Dinardo M, Bartolomei B, Rigante D. Intravenous immunoglobulin in Henoch-Schönlein purpura complicated by cerebral hemorrhage. Rheumatol Int. 2012 Jul 25. [Medline].

  71. Iqbal H, Evans A. Dapsone therapy for Henoch-Schonlein purpura: a case series. Arch Dis Child. 2005 Sep. 90(9):985-6. [Medline].

  72. Donnithorne KJ, Atkinson TP, Hinze CH, et al. Rituximab therapy for severe refractory chronic Henoch-Schonlein purpura. J Pediatr. 155. 2009:136-9. [Medline].

  73. Nikibakhsh AA, Mahmoodzadeh H, Karamyyar M, et al. Treatment of complicated henoch-schonlein purpura with mycophenolate mofetil: a retrospective case series report. Int J Rheumatol. 2010 Jun. [Medline].

  74. Augusto JF, Sayegh J, Delapierre L, Croue A, Tollis F, Cousin M, et al. Addition of plasma exchange to glucocorticosteroids for the treatment of severe Henoch-Schönlein purpura in adults: a case series. Am J Kidney Dis. 2012 May. 59(5):663-9. [Medline].

  75. Shenoy M, Ognjanovic MV, Coulthard MG. Treating severe Henoch-Schonlein and IgA nephritis with plasmapheresis alone. Pediatr Nephrol. 2007 Aug. 22(8):1167-71. [Medline].

  76. Donghi D, Schanz U, Sahrbacher U, et al. Life-threatening or organ-impairing Henoch-Schonlein purpura: plasmapheresis may save lives and limit organ damage. Dermatology. 2009. 219(2):167-70. [Medline].

  77. Murgu A, Mihaila D, Cozma L, Chiforeanu AM. Indications and limitations of histopathological skin investigation of Henoch-Schönlein purpura in children. Rom J Morphol Embryol. 2012. 53(3 Suppl):769-73. [Medline].

  78. Marmon S, Shek SY, Yeung CK, Chan NP, Chan JC, Chan HH. Evaluating the safety and efficacy of the 1,440-nm laser in the treatment of photodamage in Asian skin. Lasers Surg Med. 2014 Jul. 46(5):375-9. [Medline].

Purpuric papules and plaques of the lower extremity characteristic of Henoch-Schönlein purpura.
Hemorrhagic macules, papules, and patches on the ankle and foot of a child with Henoch-Schönlein purpura.
Typical rash distribution of Henoch-Schönlein purpura.
Characteristic rash of Henoch-Schönlein purpura.
Older lesions of Henoch-Schönlein purpura demonstrating increased extravasation with ecchymoses on dorsal foot and ankle.
A 9-year-old boy with Henoch-Schönlein purpura. Note confluence of purpura around the ankles. Image courtesy of Pamela L Dyne, MD.
A 7-year-old girl with Henoch-Schönlein purpura. Image courtesy of Pamela L Dyne, MD.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.